Review
Copyright ©The Author(s) 2022.
World J Clin Oncol. Jun 24, 2022; 13(6): 448-472
Published online Jun 24, 2022. doi: 10.5306/wjco.v13.i6.448
Table 4 Ongoing clinical trials investigating immune checkpoint inhibitor - based clinical trials in the adjuvant and neoadjuvant setting
NCT
Phase
Study drugs
Treatment setting
Endpoint
Estimated End of Trial
NCT03383458 3NIVOLUMAB vs PLACEBOAdjuvantRFSJune 2025
NCT03867084 3PEMBROLIZUMAB vs PLACEBOAdjuvantRFS, OSJune 2025
NCT03847428 3DURVALUMAB + BEVACIZUMAB vs PLACEBOAdjuvantRFSSeptember 2023
NCT04102098 3ATEZOLIZUMAB + BEVACIZUMAB vs PLACEBOAdjuvantRFSJuly 2027
NCT03859128 2/3TORIPALIMAB vs PLACEBOAdjuvantRFSApril 2024
NCT03839550 2CAMRELIZUMAB + APATINIBAdjuvantRFSFebruary 2023
NCT04418401 2ANTI-PD1 + DONAFINIBAdjuvantRFSJune 2023
NCT03510871 2NIVOLUMAB + IPILIMUMABNeoadjuvantORR, downstaging rateDecember 2022
NCT04123379 2NIVOLUMAB + CCR2/5-inhibitor vs NIVOLUMAB +ANTI-IL8NeoadjuvantSafetyOctober 2024
NCT03222076 2NIVOLUMABNeoadjuvantSafetySeptember 2022
NCT03682276 1/2NIVOLUMAB + IPILIMUMABNeoadjuvantSafety, Delay to surgerySeptember 2022
NCT03383458 1NIVOLUMAB vs PLACEBOAdjuvantRFSJune 2025
NCT04425226N/APEMBROLIZUMAB + LENVATINIBNeoadjuvantRFS, ORRDecember 2025